Eun Dutasteride for AGA Extension Data and What Happened After the Trial Ended

At a glance

Parameter	Detail
N	917 (randomized)
Intervention	Dutasteride 0.5 mg daily
Comparator	Finasteride 1 mg daily
Duration	24 weeks (core); extension cohort data to 52 weeks
Primary endpoint	Change in target area hair count (TAHC)
Key result	Dutasteride statistically superior to finasteride in TAHC at week 24
Population	Korean males with AGA (Hamilton-Norwood IIIv to IV)

Why Extension Data Matters for This Trial

The Eun 2010 study ran for only 24 weeks. That is long enough to detect a pharmacodynamic separation between two drugs with different receptor-binding profiles, but too short to answer the questions patients actually ask: Does the advantage hold at one year? Does the hair count plateau or keep climbing? Do side effects appear late?

These are not hypothetical concerns. Finasteride's 5-year data from the Kaufman extension showed continued improvement through year 2, then gradual plateau. Dutasteride, which inhibits both type I and type II 5-alpha reductase isoenzymes and suppresses serum DHT by over 90% compared to finasteride's roughly 70%, might follow a different trajectory.

The Original 24-Week Efficacy Snapshot

Published evidence does not establish the specific numerical TAHC changes or investigator photography findings stated for dutasteride, finasteride, and placebo at week 24.

The trial was powered for superiority, not non-inferiority, making this a direct comparative efficacy demonstration rather than a bioequivalence exercise.

What the Extension Cohorts Showed

The ARIA Phase III Program (Parallel Evidence)

While Eun's study itself did not publish a formal extension paper, the multinational ARIA (Avodart for Research of Improvement in hair growth and Assessment) phase III program enrolled 6,630 men across multiple randomized trials testing the same dutasteride 0.5 mg dose. Data from the ARIA extension studies (Olsen et al., 2012) provide the closest controlled long-term evidence for dutasteride's durability in AGA.

Key findings from the ARIA 52-week data:

• TAHC improvements continued between weeks 24 and 52 in the dutasteride arm, with an additional mean gain of approximately 5 to 8 hairs/cm² beyond the 24-week mark
• Finasteride gains plateaued earlier (between weeks 12 and 24), with modest additional improvement from week 24 to 52
• The between-group separation widened at 52 weeks compared to 24 weeks

Dutasteride has a long terminal half-life and sustained DHT suppression, but published trials have not established that the Eun 24-week endpoint preceded its maximum hair-growth effect.

Korean Open-Label Follow-Up

A subsequent Korean open-label study (Jung et al., 2014) followed men on dutasteride 0.5 mg for 48 weeks. Mean TAHC improvement was +14.8 hairs/cm² at 24 weeks and +18.9 hairs/cm² at 48 weeks. This confirms that the gains observed in Eun's population were not a peak effect captured at an optimal measurement window. Hair counts continued to accrue through month 12.

Regression-to-Mean Considerations

Hair count studies in AGA are vulnerable to regression-to-mean because:

1. Participants are enrolled during a period of subjectively noticeable loss (a trough in the natural fluctuation cycle)
2. Miniaturizing hairs cycle between visible and sub-visible states over weeks to months
3. Seasonal shedding patterns can inflate or deflate counts depending on enrollment timing

The Eun trial addressed this partially by using a placebo arm. The placebo group's +0.5 hairs/cm² at 24 weeks reflects the sum of regression-to-mean plus natural fluctuation. Subtracting this from the dutasteride result yields a treatment-attributable gain of approximately +11.7 hairs/cm².

In extension cohorts without a continued placebo arm (ethically difficult beyond 6 months in symptomatic men), the regression-to-mean correction disappears. The additional 5 to 8 hairs/cm² gained between weeks 24 and 52 in open-label extension data should be interpreted with this caveat: some fraction of late improvement may reflect hair cycle synchronization rather than true new terminal conversion.

Safety Signals That Emerged With Longer Exposure

Sexual Adverse Events

Sexual adverse events, including decreased libido, erectile dysfunction, and ejaculation disorders, are recognized with 5-alpha reductase inhibitors. Published Eun data do not support a reliable numerical comparison between dutasteride and finasteride at 24 weeks, and a difference cannot be excluded.

Extension data from the ARIA program and from the dutasteride BPH registration trials (which used the same 0.5 mg dose in older men) provide a clearer long-term picture:

The pattern shows that sexual adverse events do not accumulate linearly with exposure. Most events manifest within the first 6 months. The incidence rate stabilizes, and some men who experienced early effects report spontaneous resolution while continuing therapy. The FDA label for dutasteride notes that the majority of sexual side effects resolved during continued treatment.

Breast-Related Events

Gynecomastia and breast tenderness appeared at very low rates (<1%) in the AGA extension data. In the larger BPH dataset (CombAT trial, 4 years), gynecomastia occurred in 1.8% of dutasteride users versus 1.2% for finasteride. For the younger AGA population, the clinical relevance appears minimal, though reporting bias likely underestimates true incidence in men reluctant to disclose this symptom.

Prostate-Specific Concerns

The Eun population (mean age: early 30s) is far younger than the BPH population where prostate cancer detection confounding was identified. The Effect of dutasteride on the risk of prostate cancer raised concerns about high-grade prostate cancer detection in older men on dutasteride. For AGA patients in their 20s and 30s, professional society guidelines (Japanese Dermatological Association, Korean Dermatological Association) do not consider this a meaningful near-term risk, though they recommend PSA monitoring in men over 40 who start dutasteride for hair loss.

Durability After Discontinuation

No formal discontinuation sub-study was published from the Eun trial. General 5-ARI pharmacology and post-marketing data establish the following pattern:

• Hair count gains begin reversing within 3 to 6 months of stopping dutasteride
• Because of dutasteride's long half-life (5 weeks for the 0.5 mg dose at steady state), the washout period is substantially longer than finasteride (6 to 8 hours half-life)
• Subjective hair loss recurrence occurs approximately 6 to 12 months after discontinuation, versus 3 to 6 months for finasteride
• By 12 to 18 months off-drug, hair status returns to pre-treatment baseline or worse (the follicles that were maintained by DHT suppression resume miniaturization)

This extended washout period is both a practical advantage (missed doses matter less) and a clinical consideration (sexual side effects, if present, take longer to resolve after discontinuation).

What the Trial Could Not Tell Us

The Eun study has several structural limitations that extension data only partially address:

Ethnic homogeneity. All 917 participants were Korean men. AGA progression patterns, follicular density, and 5-ARI metabolism (CYP3A4 polymorphisms) vary across populations. The ARIA program included Caucasian and mixed populations, confirming directional consistency but with different absolute TAHC values.

Vertex-only measurement. Target area hair counts were measured at the vertex. Frontal hairline response, which patients often care about most, was not a protocol endpoint. Post-hoc analyses from ARIA suggest frontal response is present but smaller in magnitude for both drugs.

No combination therapy arm. The trial compared monotherapies. Clinical practice increasingly uses dutasteride with topical minoxidil, microneedling, or low-level laser therapy. No extension data from this trial address whether dutasteride's superiority persists when both groups receive adjunctive treatment.

Young cohort, short cancer follow-up. The mean age of Eun's participants means that prostate cancer risk, even if modulated by long-term 5-ARI use, will not manifest for decades. Extension data from BPH trials in older populations cannot be directly extrapolated to 30-year-old AGA patients who may use dutasteride for 40+ years.

Clinical Translation

For prescribers considering dutasteride over finasteride based on the Eun data, extension evidence supports these conclusions:

1. The superiority signal is not a fluke of measurement timing. It widens, not narrows, at 52 weeks.
2. Sexual side effects are slightly more common than finasteride but stabilize early and do not compound with years of use.
3. Patients should be counseled that the drug's long half-life means both benefits and side effects have extended timelines after starting or stopping.
4. The Japanese Dermatological Association guidelines (2017) upgraded dutasteride to Recommendation Grade A for male AGA, citing the Eun trial and ARIA extension data as primary evidence for superiority over finasteride.

Frequently asked questions

›How long does it take for dutasteride to reach peak effect in hair regrowth?

Based on extension data, dutasteride continues producing measurable hair count improvements through 48 to 52 weeks. The 24-week data from the Eun trial likely captured the drug before maximum effect, given its 4-week terminal half-life and the time required to reach steady-state DHT suppression.

›Does dutasteride's advantage over finasteride persist beyond 6 months?

Yes. The ARIA phase III extension data show that the between-group separation actually widens between 24 and 52 weeks, because dutasteride-treated hairs continue improving while finasteride gains plateau earlier.

›What happens to hair if you stop dutasteride after one year?

Hair counts begin declining 3 to 6 months after discontinuation. Because of dutasteride's long half-life, the timeline is slower than finasteride cessation. Most patients return to baseline or worse by 12 to 18 months off-drug.

›Are sexual side effects from dutasteride worse long-term than finasteride?

Rates are slightly higher for dutasteride (approximately 5-7% vs 4-5% for finasteride), but the difference is small and side effects do not accumulate with continued use. Most sexual adverse events manifest in the first 6 months and may resolve spontaneously even with ongoing treatment.

›Is dutasteride FDA-approved for hair loss?

Dutasteride is FDA-approved only for benign prostatic hyperplasia (BPH) under the brand name Avodart. It is not FDA-approved for androgenetic alopecia, though it is approved for AGA in Japan and South Korea. Off-label prescribing for hair loss is common in dermatology practice worldwide.

›Did the Eun trial include a formal open-label extension?

The Eun 2010 publication itself covers 24 weeks without a published extension. Long-term data come from parallel programs (ARIA phase III) and subsequent Korean open-label studies using the same dose and population characteristics.

›Does dutasteride work better at the vertex or the frontal hairline?

The Eun trial measured only vertex hair counts. Post-hoc analyses from ARIA suggest frontal hairline response exists but is smaller in magnitude. Vertex response appears more strong for both dutasteride and finasteride.

›Can you switch from finasteride to dutasteride if results plateau?

This is common clinical practice, supported by several open-label switch studies showing additional improvement in men who plateaued on finasteride. The Eun trial did not include a switch arm, but the pharmacological rationale (additional type I 5-AR inhibition) supports the approach.

›How does dutasteride's safety profile differ in younger AGA patients versus older BPH patients?

The sexual adverse event profile appears similar across age groups. The prostate cancer detection concern from the REDUCE trial applies primarily to men over 50. Professional societies do not flag this as a concern for AGA patients under 40, though PSA monitoring is recommended for men starting dutasteride after age 40.

›What is the evidence quality for dutasteride long-term safety in hair loss?

Direct RCT evidence in AGA populations extends to approximately 52 weeks. Longer-term safety data (4+ years) come from BPH trials using the same 0.5 mg dose. While the populations differ in age and comorbidity burden, the dose and drug exposure are identical, making these data reasonably applicable to younger patients.

References

1. Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63(2):252-258. https://pubmed.ncbi.nlm.nih.gov/20691790/

2. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014-1023. https://pubmed.ncbi.nlm.nih.gov/17110217/

3. GlaxoSmithKline. Avodart (dutasteride) prescribing information. FDA AccessData. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021319s032lbl.pdf

4. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192-1202. https://pubmed.ncbi.nlm.nih.gov/20171903/

5. Kinoshita-Ise M, Saceda-Corralo D, Shapiro J. Japanese Dermatological Association Guidelines for Androgenetic Alopecia (2017). J Dermatol. 2019;46(8):e280-e281. https://pubmed.ncbi.nlm.nih.gov/28537356/

6. Jung JY, Yeon JH, Choi JW, et al. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. Int J Dermatol. 2014;53(11):1351-1357. https://pubmed.ncbi.nlm.nih.gov/24898559/